Dose dependent effects of tadalafil and roflumilast on ovalbumin-induced airway hyperresponsiveness in guinea pigs

References

• Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use. Pharmacol Rev. 2006;58:488–520.
   PubMed Web of Science ®Google Scholar
• Mokry J, Mokra D. Immunological aspects of phosphodiesterase inhibition in the respiratory system. Respir Physiol Neurobiol. 2013;187(1):11–7.
   PubMed Web of Science ®Google Scholar
• Urbanova A, Kertys M, Simekova M, et al. Bronchodilator and Anti-Inflammatory Action of Theophylline in a Model of Ovalbumin-Induced Allergic Inflammation. Adv Exp Med Biol. 2016;935:53–62.
   PubMed Web of Science ®Google Scholar
• Kawamatawong T. Roles of roflumilast, a selective phosphodiesterase 4 inhibitor, in airway diseases. J Thorac Dis. 2017;9(4):1144–1154.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Frontrunners in novel pharmacotherapy of COPD. Curr Opinion Pharmacol. 2008;8:300–7.
   PubMed Web of Science ®Google Scholar
• Page CP, Spina D. Selective PDE inhibitors as novel treatments for respiratory diseases. Curr Opin Pharmacol. 2012;12(3):275–86
   PubMed Web of Science ®Google Scholar
• Rabe KF. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol. 2011;163(1):53–67.
   PubMed Web of Science ®Google Scholar
• Hatzelmann A, Morcillo EJ, Lungarella G, et al. The preclinical pharmacology of roflumilast–a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2010;23(4):235–56.
   PubMed Web of Science ®Google Scholar
• Meltzer EO, Chervinsky P, Busse W, et al. Roflumilast for asthma: Efficacy findings in placebo-controlled studies. Pulm Pharmacol Ther. 2015;35:S20–7.
   PubMed Web of Science ®Google Scholar
• Bardin P, Kanniess F, Gauvreau G, Bredenbröker D, Rabe KF. Roflumilast for asthma: Efficacy findings in mechanism of action studies. Pulm Pharmacol Ther. 2015;35:S4–10.
   PubMed Web of Science ®Google Scholar
• Patel TR, Sur S. IgE and eosinophils as therapeutic targets in asthma. Curr Opin Allergy Clin Immunol. 2017;17(1):42–49.
   PubMed Web of Science ®Google Scholar
• Louie S, Zeki AA, Schivo M, et al. The asthma-chronic obstructive pulmonary disease overlap syndrome: pharmacotherapeutic considerations. Expert Rev Clin Pharmacol. 2013;6(2):197–219.
   PubMed Web of Science ®Google Scholar
• Matera MG, Page C, Cazzola M. PDE inhibitors currently in early clinical trials for the treatment of asthma. Expert Opin Investig Drugs. 2014;23(9):1267–75.
   PubMed Web of Science ®Google Scholar
• Bateman ED, O'Byrne PM, Buhl R, Rabe KF. Roflumilast for asthma: Weighing the evidence. Pulm Pharmacol Ther. 2015;35:S1–3.
   PubMed Web of Science ®Google Scholar
• Boswell-Smith V, Spina D, Page CP. Phosphodiesterase inhibitors. Br J Pharmacol. 2006;147(Suppl 1):S252–7.
   PubMed Web of Science ®Google Scholar
• Dupont LL, Glynos C, Bracke KR, Brouckaert P, Brusselle GG. Role of the nitric oxide-soluble guanylyl cyclase pathway in obstructive airway diseases. Pulm Pharmacol Ther. 2014;29(1):1–6.
   PubMed Web of Science ®Google Scholar
• Wollin L, Bundschuh DS, Wohlsen A, Marx D, Beume R. Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors. Pulm Pharmacol Ther. 2006;19(5):343–52.
   PubMed Web of Science ®Google Scholar
• Wollin L, Marx D, Wohlsen A, Beume R. Roflumilast inhibition of pulmonary leukotriene production and bronchoconstriction in ovalbumin-sensitized and -challenged Guinea pigs. J Asthma. 2005;42(10):873–8.
   PubMed Web of Science ®Google Scholar
• Takeda K, Shiraishi Y, Domenico J, et al. Combined effects of the phosphodiesterase type 4 (PDE4) inhibitor, roflumilast, and the PDE5 inhibitor, tadalafil, in allergen-induced airway hyperresponsiveness (AHR). Am J Crit Care Med. 2009;179:A5717.
   Web of Science ®Google Scholar
• Mokry J, Nosalova G, Mokra D. Influence of xanthine derivatives on cough and airway reactivity in guinea pigs. J Physiol Pharmacol. 2009;60(Suppl 5):87–91.
   PubMed Web of Science ®Google Scholar
• Pennock BE, Cox CP, Rogers RM, Cain WA, Wells JH. A noninvasive technique for measurement of changes in specific airway resistance. J Appl Physiol Respir Environ Exerc Physiol. 1979;46(2):399–406.
   PubMed Web of Science ®Google Scholar
• Mokry J, Mokra D, Nosalova G, Beharkova M, Feherova Z. Influence of selective inhibitors of phosphodiesterase 3 and 4 on cough and airway reactivity. J Physiol Pharmacol. 2008;59(Suppl 6):473–82.
   PubMed Web of Science ®Google Scholar
• Tagaya E, Tamaoki J. Mechanisms of airway remodeling in asthma. Allergol Int. 2007;56(4):331–40.
   PubMedGoogle Scholar
• Toward TJ, Broadley KJ. Early and late bronchoconstrictions, airway hyper-reactivity, leucocyte influx and lung histamine and nitric oxide after inhaled antigen: effects of dexamethasone and rolipram. Clin Exp Allergy. 2004;34(1):91–102.
   PubMed Web of Science ®Google Scholar
• Chung KF. Phosphodiesterase inhibitors in airways disease. Eur J Pharmacol. 2006;533:110–7.
   PubMed Web of Science ®Google Scholar
• Giembycz MA. Phosphodiesterase-4: Selective and Dual-Specificity Inhibitors for the Therapy of Chronic Obstructive Pulmonary Disease. Proc American Thor Soc. 2005b;2:326–33.
   PubMedGoogle Scholar
• Rabe KF, Bateman ED, O`Donnell D, Witte S, Bredenbroker D, Bethke TD. Roflumilast – an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2005;366:563–71.
   PubMed Web of Science ®Google Scholar
• Mokrý J, Urbanová A, Medvedová I, et al. Effects of Selective Inhibition of PDE4 by YM976 on Airway Reactivity and Cough in Ovalbumin-Sensitized Guinea Pigs. Adv Exp Med Biol. 2016;921:61–70.
   PubMed Web of Science ®Google Scholar
• Karish SB, Gagnon JM. The potential role of roflumilast: the new phosphodiesterase-4 inhibitor. Ann Pharmacother. 2006;40(6):1096–104.
   PubMed Web of Science ®Google Scholar
• Kim SW, Kim JH, Park CK, et al. Effect of roflumilast on airway remodelling in a murine model of chronic asthma. Clin Exp Allergy. 2016;46(5):754–63.
   PubMed Web of Science ®Google Scholar
• Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, Beume R. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther. 2001;297(1):280–90.
   PubMed Web of Science ®Google Scholar
• Hart PH. Regulation of the inflammatory response in asthma by mast cell products. Immunol Cell Biol. 2001;79(2):149–53.
   PubMed Web of Science ®Google Scholar
• Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature. 2008;454(7203):445–54.
   PubMed Web of Science ®Google Scholar
• Djukanović R. Asthma: A disease of inflammation and repair. J Allergy Clin Immunol. 2000;105(2 Pt 2):S522–6.
   PubMed Web of Science ®Google Scholar
• Martin-Chouly CA, Astier A, Jacob C, Pruniaux MP, Bertrand C, Lagente V. Modulation of matrix metalloproteinase production from human lung fibroblasts by type 4 phosphodiesterase inhibitors. Life Sci. 2004;75(7):823–40.
   PubMed Web of Science ®Google Scholar
• Murad HA, Habib HS, Rafeeq MM, Sulaiman MI, Abdulrahman AS, Khabaz MN. Co-inhalation of roflumilast, rather than formoterol, with fluticasone more effectively improves asthma in asthmatic mice. Exp Biol Med (Maywood). 2017;242(5):516–526.
   PubMed Web of Science ®Google Scholar
• Patel BS, Prabhala P, Oliver BG, Ammit AJ. Inhibitors of Phosphodiesterase 4, but Not Phosphodiesterase 3, Increase β2-Agonist-Induced Expression of Antiinflammatory Mitogen-Activated Protein Kinase Phosphatase 1 in Airway Smooth Muscle Cells. Am J Respir Cell Mol Biol. 2015;52(5):634–40.
   PubMed Web of Science ®Google Scholar
• Toward TJ, Smith N, Broadley KJ. Effect of phosphodiesterase-5 inhibitor, sildenafil (Viagra), in animal models of airways disease. Am J Respir Crit Care Med. 2004;169:227–34.
   PubMed Web of Science ®Google Scholar
• Sousa CT, Brito TS, Lima FJB, et al. Sildenafil decreases rat tracheal hyperresponsiveness to carbachol and changes canonical transient receptor potential gene expression after antigen challenge. Braz J Med Biol Res. 2011;44(6):562–572.
   PubMed Web of Science ®Google Scholar
• Mullershausen F, Lange A, Mergia E, Friebe A, Koesling D. Desensitization of NO/cGMP signaling in smooth muscle: blood vessels versus airways. Mol Pharmacol. 2006;69(6):1969–74.
   PubMed Web of Science ®Google Scholar
• Clayton RA, Dick CA, Mackenzie A, et al. The effect of selective phosphodiesterase inhibitors, alone and in combination, on a murine model of allergic asthma. Respir Res. 2004;5:4.
   PubMed Web of Science ®Google Scholar
• Al Qadi-Nassar B, Bichon-Laurent F, Portet K, Tramini P, Arnoux B, Michel A. Effects of L-arginine and phosphodiesterase-5 inhibitor, sildenafil, on inflammation and airway responsiveness of sensitized BP2 mice. Fundam Clin Pharmacol. 2007;21(6):611–20.
   PubMed Web of Science ®Google Scholar
• Sawamura F, Kato M, Fujita K, Nakazawa T, Beardsworth A. Tadalafil, a long-acting inhibitor of PDE5, improves pulmonary hemodynamics and survival rate of monocrotaline-induced pulmonary artery hypertension in rats. J Pharmacol Sci. 2009;111:235–43.
   PubMed Web of Science ®Google Scholar
• Giembycz MA. Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors. Curr Opin Pharmacol. 2005a;5:238–44.
   PubMed Web of Science ®Google Scholar
• Giembycz MA, Maurice DH. Cyclic nucleotide-based therapeutics for chronic obstructive pulmonary disease. Curr Opin Pharmacol. 2014;16:89–107.
   PubMed Web of Science ®Google Scholar